Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study

BACKGROUND: According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2−) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily practice. The objectives of this study wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Julien, Chaix, Marie, Billa, Oumar, Kamga, Ariane Mamguem, Roignot, Patrick, Ladoire, Sylvain, Coutant, Charles, Arveux, Patrick, Quantin, Catherine, Dabakuyo-Yonli, Tienhan Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525445/
https://www.ncbi.nlm.nih.gov/pubmed/32678278
http://dx.doi.org/10.1038/s41416-020-0979-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525445/
https://www.ncbi.nlm.nih.gov/pubmed/32678278
http://dx.doi.org/10.1038/s41416-020-0979-3

Ejemplares similares